Drugs / Salmeterol/fluticasone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00669617 | Apr → Aug 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmeterol/fluticasone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00669617 ↗ |
| Route | Inhaled | “Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).” NCT00669617 ↗ |